| Summary: | Utkarsh H Acharya, Joanne M Jeter Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administration for the treatment of metastatic melanoma. Phase III trials have demonstrated an overall survival benefit with its use when compared with standard treatments and other investigational therapies. However, the drug poses a notable challenge, given its propensity for toxicity, and requires close surveillance when administered in clinical practice. This review discusses the mechanism of action for ipilimumab, its preclinical data, and the clinical trials that led to its approval by the Food and Drug Administration in 2011. Keywords: melanoma, immunotherapy, ipilimumab
|
|---|
